title: [Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
abstract: Numerous studies have demonstrated that a significant change in weight during chemotherapy treatment was a factor of poor prognosis in early breast cancer women. However, the causes and mechanisms involved in this phenomenon are not fully known. This review summarizes current knowledge about the causes of energy imbalance during chemotherapy treatment and the mechanisms that have been proposed as responsible for the increased risk of relapse and death in this population. Current preventive strategies focus on physical activity programs but also on the use of metformin during and after chemotherapy.
authors.affiliation: Centre Jean-Perrin, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 1, France, Inra/UdA, UMR 1019 Human Nutrition, CHLEO, 63000 Clermont-Ferrand, France, Centre d'investigation clinique, 63000 Clermont-Ferrand, France.
authors.forename: Émilie
authors.initials: É
authors.lastname: Gadéa
authors.forename: Émilie
authors.initials: É
authors.lastname: Thivat
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang-Lopez
authors.forename: Marie
authors.initials: M
authors.lastname: Viala
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Paulon
authors.forename: Éloïse
authors.initials: É
authors.lastname: Planchat
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Chadeyras
authors.forename: Charles
authors.initials: C
authors.lastname: Merlin
authors.forename: Bruno
authors.initials: B
authors.lastname: Coudert
authors.forename: Yves-Jean
authors.initials: YJ
authors.lastname: Bignon
authors.forename: Béatrice
authors.initials: B
authors.lastname: Morio
authors.forename: Xavier
authors.initials: X
authors.lastname: Durando
mesh_terms: D050154:Adiposity / Q000502:physiology; D000970:Antineoplastic Agents / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D015444:Exercise / Q000502:physiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D064797:Physical Conditioning, Human; D015430:Weight Gain / Q000502:physiology*; D015431:Weight Loss / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D008687:Metformin
keywords: breast cancer; chemotherapy; insulin resistance; prognosis; weight change